Recombinant Human herpesvirus 1 Envelope glycoprotein G (gG)-VLPs are engineered structures designed to mimic viral particles while incorporating the gG protein from herpes simplex virus type 1 (HSV-1). These VLPs (Virus-Like Particles) lack genomic material, making them safe for research and therapeutic applications. The gG protein, encoded by the HSV-1 US4 gene, is critical for viral entry and immune evasion . By integrating this protein into VLPs, researchers aim to leverage its immunogenic properties for serodiagnosis, vaccine development, and studies of viral pathogenesis.
The table below contrasts gG-VLPs with established VLP systems, highlighting their unique advantages:
| VLP Type | Antigen | Platform | Key Applications | Immune Response |
|---|---|---|---|---|
| HSV-1 gG-VLPs | gG (US4) | Lipid nanoparticles | HSV-1 serodiagnosis, vaccines | Neutralizing antibodies, TH1 |
| HIV gp120-VLPs | HIV-1 envelope | Sf9 insect cells | HIV vaccine development | Broad neutralizing responses |
| HBV HBsAg-VLPs | Hepatitis B surface | Pichia pastoris | Hepatitis B vaccines | Strong IgG and IgA responses |
Data adapted from and analogous systems.
Optimized Formulations: Testing gG-VLPs in combination with adjuvants or other viral antigens (e.g., gD) to broaden immune coverage.
Clinical Translation: Leveraging VLP scalability for large-scale production of HSV-1 diagnostic kits or prophylactic vaccines.
KEGG: vg:2703404